Figure 1From: Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseasesInitial infliximab dose for patients positive and negative for antibodies toward infliximab (ATI pos and ATI neg , respectively). Box plots show the medians and interquartile ranges, and the whisker plots represent the 95th percentiles. Two patients in the RA subgroup (open circles) received 5 mg/kg infliximab at initiation because they were initially suspected of having psoriatic arthritis. During follow-up, anticitrullinated protein antibodies were detected in both patients, which explains their placement in the RA subgroup. Two patients with SpA (open circles) received 3 mg/kg infliximab at initiation because they had a peripheral form of the disease and were therefore misclassified as having RA. ATI: antibodies toward infliximab; ATIpos: ATI detected at least once during follow-up; ATIneg: ATI not detected; RA: rheumatoid arthritis; SpA: spondyloarthritis.Back to article page